SCHEMBL25835403

SCHEMBL25835403

CCCCCCCC/C=C\CCCCCCCCCCCC(=O)NCCOCCNC(=O)CCOCCCl

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 2/20 0.62
LPAR2 Q9HBW0 2/20 0.62
ENPP2 Q13822 1/20 0.62
CNR1 P21554 4/20 0.60
ALDH1A1 P00352 3/20 0.60
HPGD P15428 3/20 0.60
FAAH O00519 3/20 0.60
MAPT P10636 2/20 0.60
ALOX12 P18054 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
CNR2 P34972 1/20 0.60
EPHX2 P34913 2/20 0.58
SLC6A5 Q9Y345 2/20 0.56
TRPV1 Q8NER1 1/20 0.56
MEN1 O00255 1/20 0.56
BLM P54132 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25835398 0.96 CNR1 (0.67) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL25835554 0.92 FAAH (0.66) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL26032911 0.91 FAAH (0.64) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL25835512 0.89 FAAH (0.70) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL26032894 0.88 FAAH (0.68) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL25835638 0.87 LPAR1 (0.67) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL26032862 0.86 SLC6A5 (0.66) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL4387701 0.85 CNR1 (0.68) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL24022038 0.84 CNR1 (0.67) LPAR1LPAR2ENPP2CNR1ALDH1A1
SCHEMBL4392061 0.84 SLC6A5 (0.71) LPAR1LPAR2ENPP2CNR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 LPAR1 147/4885LPAR2 74/4885ENPP2 658/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 LPAR1 1841/4885LPAR2 1529/4885ENPP2 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.